Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Andreas von Planta 
        • Charles Sawyers 
        • William Winters 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab About Novartis
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • COVID-19: Patients and Caregivers 
      • Stories: Patients Perspectives 
      Couple holding hands Patients & Caregivers
    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • Abstract summaries for EADV 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor Healthcare Professionals
    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Immuno-oncology research at Novartis 
        • Oncology research at Novartis 
        • Cardiovascular and metabolic disease research at Novartis 
        • Autoimmunity, transplantation and inflammatory disease research at Novartis 
        • Ophthalmology research at Novartis 
        • Neuroscience Research at Novartis 
        • Musculoskeletal Disease Research at Novartis 
        • DAx: exploratory disease research at Novartis 
      • Research Locations 
        • Novartis Institute for Tropical Diseases 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research & Development Approach 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments Research & Development
    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda Environmental, Social and Governance
    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube Investors
    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens News
    • Careers 
      • Career Search 
      • Our Teams 
        • Careers in Commercial 
        • Careers in Communications and Engagement 
        • Careers in Consulting 
        • Careers in Digital 
        • Careers in Health, Safety & Environment 
        • Careers in Information Technology (IT) 
        • Careers in Medical & Development 
        • Careers in People & Organization 
        • Careers in Procurement 
        • Careers in Research 
        • Careers in Strategy 
        • Careers in Manufacturing and Supply 
        • Ethics, Risk & Compliance (ERC) 
        • Careers in Legal 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Talent 
        • US NIBR Internship Programs 
      • International Careers 
      • Personal Growth 
      • Well-being 
      A female Novartis researcher Careers
    • Clinical Trials 
      doctor taking the blood pressure of her patient Clinical Trials
    • Partnering 
      Business people working in a dark room Partnering
    • Supplier Portal 
    • Report side effects 
    • Contacts 
      Office Cubicle Contacts
    Visitors enjoying the visit of the Novartis Pavillon Home
  • People and Culture
    A scientist from the start – Q&A with NIBR President Fiona Marshall
    Biomedical ResearchNovartis Institutes for BioMedical ResearchScientific ResearchDrug DevelopmentWomen in Science
  • Access to Healthcare
    Renewing our commitment to neglected tropical disease and malaria elimination

    Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

    Access to HealthcareClinical ResearchDrug DevelopmentInfectious DiseasesTropical Diseases
  • Novartis at ASCO and EHA 2022
    Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need.
    CancerDisease AwarenessDrug DevelopmentOncology
  • Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
    Basel, January 10, 2022 — Novartis and Molecular Partners today announced that Part A of the EMPATHY clinical trial1 that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. The two secondary endpoints also showed…
    Reimagine MedicineInnovationDrug Development
  • Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)
    Ad hoc announcement pursuant to Art. 53 LR
    Reimagine MedicineDrug DevelopmentAd Hoc
  • Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
    Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company’s progress in advancing its industry-leading R&D engine.
    InnovationFuture of HealthcareDrug Development
  • Discovery
    The art of drug design in a technological age

    Novartis is collaborating with Microsoft to apply machine learning to medicinal chemistry — part of an effort to leverage AI to bring treatments to patients more efficiently.

    Biomedical ResearchData ScienceDrug DevelopmentDrug DiscoveryEmerging Technology
  • Access to Healthcare
    To make a difference, start with patients

    John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

    Drug DevelopmentInnovationWorking at Novartis
  • Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
    Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this…
    Drug DevelopmentClinical TrialsAd Hoc
  • Novartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
    Basel, October 9, 2020 — Novartis today announced that the European Medicines Agency (EMA) has granted PRIME designation for iptacopan (LNP023) in C3 glomerulopathy (C3G). PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced…
    Reimagine MedicineDrug Development
  • En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
    Bâle, le 26 janvier 2021 - En commentant les résultats, Vas Narasimhan, CEO de Novartis, a déclaré: «En dépit des défis posés par le Covid-19, Novartis a réalisé une excellente performance en 2020 dans toutes ses priorités stratégiques. Sur le plan opérationnel, nous avons augmenté notre chiffre d’affaires et continué d’améliorer nos marges…
    Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare
  • Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
    Basel, 26. Januar 2021 — Die Ergebnisse 2020 kommentierte Vas Narasimhan, CEO von Novartis: «Novartis hat 2020 trotz der Herausforderungen durch COVID-19 bei allen strategischen Prioritäten solide Ergebnisse erzielt. Operativ konnten wir den Umsatz steigern und die operativen Kerngewinnmargen bei Innovative Medicines verbessern. Wir haben unsere…
    Reimagine MedicineFuture of HealthcareDrug DevelopmentAd HocAccess to Healthcare

Pagination

  • 1
  • 2
  • 3
  • 4
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience